Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia: case-based session.

K R Rai1, H Döhner, M J Keating

  • 1Division of Hematology-Oncilogy, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA.

Hematology. American Society of Hematology. Education Program
|November 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.

Bone marrow transplantation·2020
Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017
Same author

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Younger Adults: Preliminary Results of a Study Based on 454 Patients-IWCLL/Working Group.

Leukemia & lymphoma·2016
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with distinct subtypes. Understanding these differences, including genetic mutations and chromosomal abnormalities, improves prognosis and treatment strategies for CLL patients.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous hematological malignancy.
  • Past understanding relied on empirical observations; current research elucidates scientific mechanisms of CLL heterogeneity.
  • Recent advancements have significantly accelerated progress in understanding and treating CLL.

Purpose of the Study:

  • To review the clinical features of chronic lymphocytic leukemia (CLL).
  • To explain the scientific basis for CLL heterogeneity.
  • To discuss recent therapeutic advances and ongoing studies in CLL management.

Main Methods:

  • Review of current scientific literature and clinical observations.
  • Analysis of immunophenotypic markers, including somatic mutations in immunoglobulin variable region genes.

Related Experiment Videos

  • Application of fluorescence in situ hybridization (FISH) for detecting chromosomal abnormalities.

    • Main Results:

    • CLL comprises at least two distinct entities based on IgV gene mutation status, correlating with prognosis.
    • Somatic mutations in IgV genes indicate a history of germinal center traversal and a superior prognosis.
    • Chromosomal abnormalities identified by FISH significantly impact clinical behavior and patient outcomes.
    • Novel therapeutics including monoclonal antibodies (Campath-1H, rituximab) and fludarabine show promise in front-line treatment.

    Conclusions:

    • CLL heterogeneity is scientifically explained by distinct cellular origins and genetic profiles.
    • Prognosis is significantly influenced by IgV gene mutation status and chromosomal abnormalities.
    • Advances in therapeutics, including targeted antibodies and nucleoside analogs, are improving CLL treatment.
    • Combination therapies and stem cell rescue strategies are under investigation for improved patient survival.